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A B S T R A C T
The present guidelines on the management of limited disease small cell lung cancer 
(SCLC) were formulated by the ELCWP in April 2007. They are designed to answer 
the following seven questions: 1) What is the definition of limited disease? 2) Should 
chest radiotherapy be provided and what are the benefits? 3) What is the optimal 
timing and mode of administration of chest irradiation? 4) Which are the optimal 
radiotherapy parameters: dose, fractionation, target volume? 5) What is the optimal 
chemotherapy regimen for limited disease SCLC? 6) Should prophylactic cranial ir-
radiation be provided, when and for which patients? 7) What is the additional role of 
thoracic surgery in early SCLC?
I N T R O D U C T I O N
This is the fourth of a series of five articles, reporting clinical practice guidelines 
for lung cancer, formulated by the European Lung Cancer Working Party (ELCWP). 
These articles consecutively present the recommended treatment of early (resectable) 
stages of non-small cell lung cancer (NSCLC) [1], locoregionally advanced NSCLC 
[2], metastatic NSCLC [3] and small-cell lung cancer (SCLC) of limited and extensive 
stage. The rational of the reasons and methodology used for those guidelines have 
been previously reported [1].
After an extensive discussion, a consensus was reached among members of the 
Group to formulate the guidelines of treatment of limited small cell lung cancer on 
the basis of seven predefined essential questions: 1) What is the definition of limited 
disease? 2) Should chest radiotherapy be provided and what are the benefits? 3) What 
is the optimal timing and mode of administration of chest irradiation? 4) Which are 
the optimal radiotherapy parameters: dose, fractionation, target volume? 5) What is 
the optimal chemotherapy regimen for limited disease SCLC? 6) Should prophylactic 
cranial irradiation be provided and when and for which patients? 7) What is the ad-
ditional role of thoracic surgery in early SCLC?
These questions have been extensively discussed during a meeting organised in 
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October 2006 in Ostend in Belgium. The present consensus 
has been definitively approved by the Group in a final meeting 
in Brussels, in April 2007.
M E T H O D O L O G y
Guidelines were established on the basis of the various 
data published in the literature: clinical trials, systematic 
reviews and meta-analyses, guidelines from medical societ-
ies or groups. Literature was identified and analysed by the 
evidence-based medicine group of the ELCWP. The qual-
ity of published guidelines was assessed with the use of the 
AGREE instrument [4;5], allowing elimination of the worst 
ones and use of the best available ones for the establishment 
of our own guidelines. The following guidelines were selected: 
ASCO (American Society of Clinical Oncology) [6,7], BTS 
(British Thoracic Society) [8], Cancer Care Ontario Practice 
Guidelines [9,10], Royal College of Radiologists (RCR) [11], 
American College of Chest Physicians (ACCP) [12] and FN-
CLCC (Fédération Nationale des Centres de Lutte contre le 
Cancer) [13]. Selection was based on the assessment of the 
literature previously performed by the ACCP [14] and it was 
completed by the analysis using the AGREE instrument of 
other guidelines that had not been taken into consideration 
by the ACCP. This approach allowed adding to the list the 
guidelines of FNCLCC and ACCP.
Concerning limited disease small cell lung cancer specifi-
cally, guidelines were available only by Cancer Care Ontario, 
Royal College of Radiologists and ACCP.
Q U E S T I O N S  A N D  G U I D E L I N E S
Q U E S T I O N  1 :  w H A T  I S  T H E  D E F I N I T I O N  
O F  L I M I T E D  D I S E A S E ?
Two main systems can be used to define the extent of 
disease: the International Staging System (ISS) with TNM 
according to the last version published in 1997 by the UICC 
[15] or the two-stage system developed by the Veterans Ad-
ministration Lung Cancer Study Group (VALCSG) (limited 
or extensive disease) [16]. In the latter, patients with limited 
disease (Ld) have involvement restricted to the ipsilateral 
hemithorax which can be included within a single radiation 
port. The International Association for the Study of Lung 
Cancer [17] includes also in the definition of limited disease 
the presence of contralateral hilar and/or ipsilateral and/or 
contralateral supraclavicular nodes and/or of pericardial and/or 
ipsilateral pleural effusion, regardless of the cytology.
In published guidelines, the Royal College of Radiolo-
gists [11] defines limited disease as a disease confined to one 
hemithorax, including involvement of ipsi-and/or contralateral 
hilar, mediastinal or supraclavicular node while ACCP [18] 
recommends the VALCSG definition.
E L C w P  G U I D E L I N E S :
The disease should be staged according to both ISS 97 
and VALCSG definitions. The definition of limited disease 
should be improved, taking into account the tumour size and 
the volume that can be treated according to dose-volume 
histograms by the current radiotherapy techniques with a 
tolerable toxicity.
Q U E S T I O N  2 :  S H O U L D  C H E S T  R A D I O T H E R A P y 
B E  P R O V I D E D  A N D  w H A T  A R E  T H E  B E N E F I T S  ?
Chest irradiation is recommended in all published guide-
lines for limited disease SCLC. For RCR [11], it has to be given 
as consolidation in case of complete response to chemotherapy 
in order to improve local control and survival. For Ontario 
Cancer Care [9] and for ACCP [19], radiotherapy is required 
in order to improve local control and survival.
The evidence comes from 15 randomised trials [20-33] 
summarized in table 1. It should be noted that in none, mod-
ern radiotherapy techniques or modern chemotherapy were 
used and that chest radiotherapy was administered according 
to various modalities (concomitant, sequential, …). It was 
associated with a statistically significant survival benefit in 
only a few trials. Nevertheless, as shown by two meta-analyses 
performed on the data provided by the literature [34;35] and by 
one meta-analysis performed with the individual patients data 
of the randomised trials [36], there was a significant benefit in 
terms of both survival and local control. The benefit of survival 
at three years was estimated to be 5.4% [36]. For local control, 
the OR (odd ratio) for treatment benefit was 3.02 with an intra-
thoracic tumour control improved by 25.3% [34].
E L C w P  G U I D E L I N E S :
 Chest radiotherapy has to be administered at some time 
in the course of treatment (see question 3) in order to improve 
both survival and local control.
Q U E S T I O N  3 :  w H A T  I S  T H E  O P T I M A L  T I M I N G 
A N D  M O D E  O F  A D M I N I S T R A T I O N  O F  C H E S T 
I R R A D I A T I O N ?
The timing of chest irradiation has been the topic of many 
guidelines. The RCR [11] recommends chest radiotherapy as 
consolidation in all cases of complete response to chemotherapy. 
The Ontario Cancer Care Program [9] also recommends this 
treatment but without precise guidelines due to conflicting 
results for early versus late irradiation and for concurrent 
versus sequential administration.
Four meta-analyses have specifically addressed this problem 
[37-41]. Their main results are shown in table 2. All are based 
on published papers, taking into account 7 or 8 randomised 
trials for a total of more than 1500 patients and using different 
definitions for early and late irradiation. All but one [41] are 
in favour of early irradiation, although in the de Ruysscher 
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et al meta-analysis, statistically significant 5 years survival 
improvement is only obtained in favour of radiotherapy when 
it was finished within 30 days after the start of chemotherapy 
and if chemotherapy was cisplatin-based [40]. This result was 
obtained by analysing four randomised trials [39]. Early ir-
radiation was not associated with better local control rate but 
with a higher incidence of severe oesophagitis. In a subgroup 
meta-analysis. taking into account the completion or not of the 
planned chemotherapy, Spiro et al demonstrated that survival 
was improved by early irradiation only if full chemotherapy 
cycles were provided [41].
Published individual randomised trials [25,41-47] are sum-
marised in tables 3 and 4. These trials are very heterogeneous 
TABLE 1. Randomised trials comparing chest radiotherapy with chemotherapy to chemotherapy alone in small cell lung 
cancer.
Reference Chemotherapy RT Gy N pts MST
CT+ RT
MST
CT
p
Fox, 1980 [20] VAC x 10 sequential 40 73 68w 62w NA
Souhami, 1984 [21] VAC~CPA-MTX x 12 sequential 40 130 NA
Osterlind 1986 [22] CPA-MTX-VCR-CCNU x 18 m concomitant 40 145 42w 52w 0.05
Ohnoshi, 1986 [23] CPA-MTX-VCR-PCZ~VP16-AdR x 6 sequential 40 50 12m 15m NS
Bunn, 1987 [24] CPA-MTX-VCR ~ CddP-AdR-VCR x 8 concomitant 40 96 15m 11m 0.03
Perry, 1987 [25] VAC-VP16 x 18 m concomitant 50 489 14m 14m 0.001
Kies, 1987 [26] VAC-MTX-VP16 ~ CddP-VP16 x 6 sequential 48 93 0.86
Nou, 1988 [27] VAC-MTX ~ CPA-MTX-VCR-CCNU x 24 sequential 40 56 15m 15m NS
Birch I, 1988 [28] VAC x 6 fractioned 40 291 54w 46w 0.04
Birch II, 1988 [28] VAC x 6 fractioned 45 369 45w 51w 0.12
Kraft, 1990 [29] VAC x 6 sequential 50 91 13m 10m 0.02
Carlson, 1991 [30] CPA-CCNU-VCR-CddP ~ VP16-AdR-MTX x 7-10 sequential 55 48 20m 19m 0.91
Johnson, 1993 [31] VAC x 6 concomitant 45 369 14m 13m 0.08
Lebeau, 1993 [32] CPA-AdR-CCNU ~ VP16-AdR-CddP x 8 sequential 46 35 0.96
Joss, 1994 [33] AdR-VP16-CddP or CPA-VP16-AdR or MTX-
VCR-CPA ~ AdR-VP16-CddP
sequential 45 118 363d 316d 0.86
RT: radiotherapy; N: number; pts: patients; CT: chemotherapy; MST: median survival time; w: week; m: month; d: day; NA: not available; 
NS: non significant; VAC: vincristine + adriamycine + cyclophosphamide; CPA: cyclophosphamide; MTX: methotrexate; VCR: vincris-
tine; PCZ: procarbazine; VP16: etoposide; AdR: adriamycine; CddP: cisplatin.
TABLE 2. Meta-analyses concerning the timing of chest irradiation.
Reference Methodology Outcome N trials N pts Result
Fried, 2004 [37] Systematic review 2 yr survival 7 1524 S for 2-year survival in favour early RT
Huncharek, 2004 [38] Isolated 2 yr survival 8 1574 S in favour early RT
de Ruysscher, 2006 [39;40] Systematic review 2 yr & 5 yr survival 7 1514 NS* 
Spiro, 2006 [41] Isolated overall survival 8 1849 NS
N: number; yr: year; RT: radiotherapy; pts: patients; S: significant; NS: non significant.  *see comment in the text
in terms of design. In those directly comparing early versus 
late administration (table 3), some used concurrent treatments 
[25,41-44,47], others sequential treatment [45] and the last one 
compared initial concurrent chemotherapy to a late sequential 
approach [46]. Three were associated with significantly better 
survival in favour of the early concurrent arm [43,44,46]. Two 
trials (table 4) tested alternating chemotherapy and irradiation 
with, for the control arm, a late sequential approach [48] or a 
concurrent approach during the third course [49]. None was 
associated with significant difference in survival.
E L C w P  G U I D E L I N E S :
The trend is in favour of early concurrent chemo-radio-
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therapy. Early treatment means radiotherapy performed during 
the 30 days following the start of chemotherapy. This trend 
has to be confirmed by randomised trials.
Q U E S T I O N  4 :  w H I C H  A R E  T H E  O P T I M A L 
R A D I O T H E R A P y  PA R A M E T E R S : 
D O S E , F R A C T I O N A T I O N .  T A R G E T  V O L U M E ?
Only two societies have provided guidelines on this topic. 
The RCR [11] recommends a dose biologically equivalent to 
45-50 Gy with a fractionation of 2 Gy per day and using CT-
planned irradiation with lung correction; the Ontario Cancer 
Care Program [9] proposes a chest irradiation of at least 40 Gy 
in 15 fractions over 3 weeks without hyper-fractionation.
There are no meta-analysis and very few randomised 
trials available. Two (table 5) have tested hyperfractionation 
radiotherapy, one as early concurrent [50] and another as late 
concurrent [51]. Only the trial of Turrisi provides significant 
results but the problem is that the irradiation doses in the two 
arms are not biologically equivalent. In the Bonner trial, the 
hyperfractionated arm used a split-course schedule. There 
is only one randomised trial having specifically tested the 
dosage of chest irradiation [52] in a late sequential approach 
and with low doses of irradiation. Patients received 25 Gy 
in 10 fractions over 3 weeks or 37.5 Gy in 15 fractions over 
3 weeks. despite randomisation of 168 patients, no survival 
benefit was observed.
E L C w P  G U I D E L I N E S :
The dose of chest irradiation should be at least 45 Gy using 
a conventional fractionation or a biologically equivalent dose. 
EORTC Radiotherapy Group recommendations [53] should be 
respected for treatment planning and execution of radiotherapy 
as proposed in the ELCWP guidelines for unresectable non-
metastatic non-small cell lung cancer [2].
TABLE 3. Randomised trials testing early versus late chest irradiation for small cell lung cancer.
Reference Chemotherapy Radiotherapy Arm n pts MST p
Perry, 1987 [25;42] CPA-VCR- AdR/VP16 50 Gy/25x/5 w - initial (d1) concurrent 125 13.1 m NS
- late (# 4) concurrent 145 14.6 m
Murray, 1993 [43] CPA-VCR-AdR ~ CddP-VP16 40 Gy/15x/3 w - initial (w 3) concurrent 155 21.2 m 0.008
- late (>#6) concurrent 153 16 m
Jeremic, 1997 [44] CddP-VP16 54 Gy (2x/d)/
36x/18d/3,6 w
- initial (d1) concurrent 52 34 m 0.05
- late (w 6) concurrent 51 26 m
Work, 1997 [45] CddP-VP16 ~ AdR-CPA- VCR 40-45 Gy split
2x11x/ 2 w
- initial (d1) sequential 99 10.5 m NS
- late (> #6) sequential 100 12 m
Skarlos, 2001 [47] Carboplatine – VP16 HFRT 48 Gy
1,8 Gy bid 15x
-initial (cycle 1) concurrent 42 17 m NS
-late (cycle 4) concurrent 39 17 m
Takada, 2002 [46] CddP-VP16 HFRT 45 Gy/ 
30x/19d
- initial (d2) concurrent 114 27.2 m S
- late (d 84) sequential 114 19.7 m
Spiro, 2006 [41] CPA-VCR-AdR ~ CddP-VP16 40 Gy/15x/2 w - early (#2) concurrent 159 13.7 m NS
- late (#6) concurrent 166 15.1 m
N: number; pts: patients; MST: median survival time; w: week; m: month; d: day; NS: non significant; S: significant; CPA: cyclophosphamide; VCR: 
vincristine; VP16: etoposide; AdR: adriamycine; CddP: cisplatin; HFRT: hyperfractionated radiotherapy; #: cycle
TABLE 4. Randomised trials testing alternating chemotherapy and radiotherapy for small cell lung cancer.
Reference Chemotherapy Arm Radiotherapy N pts MST p
Gregor, 1997 [48] CPA-AdR-VP16 (x5) - alternating 12 Gy (in 5x) d15 #2, 3, 4, 5 169 14 m NS
- sequential (after CT) 50 Gy/20x/4w 165 15 m
Lebeau, 1999 [49] CPA-AdR-VP16-VdS - concurrent 3rd cycle: 50 Gy 82 13 m NS
- alternating 2nd, 3rd, 4th cycles: 20, 20 & 15 Gy 74 14 m
 N: number; pts: patients; MST: median survival time; w: week; m: month; d: day; NS: non significant; CPA: cyclophosphamide; VdS: vindesine; 
VP16: etoposide; AdR: adriamycine; #: cycle; CT: chemotherapy.
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Q U E S T I O N  5 :  w H A T  I S  T H E  O P T I M A L 
C H E M O T H E R A P y  R E G I M E N  F O R  L I M I T E D 
S C L C ?
Only the Ontario Cancer Care Program proposes specific 
guidelines for chemotherapy in Ld SCLC [10]. The regimen 
should be cisplatin plus etoposide or the same regimen alternat-
ing with VAC (vincristine + adriamycine + cyclosphosphamide), 
as an alternative. No anthracycline should be administered 
concurrently to chest irradiation. Standard dosage should be 
used according to the usual schedules summarized in a table 
of the publication. Etoposide should be given over 3 to 5 days. 
The optimal duration of chemotherapy is uncertain but not 
beyond 6 cycles.
A meta-analysis performed by our Group [54] has shown 
that for any stage of SCLC, the combination of cisplatin plus 
etoposide is associated with significantly better survival than 
combinations without those drugs or with etoposide alone. 
In a subgroup analysis of a randomised trial with concurrent 
chemo-radiotherapy [55], survival was significantly better in 
limited disease when chemotherapy consisted of cisplatin 
plus etoposide rather than epirubicin plus cyclophosphamide 
plus vincristine, with respective median survival times of 14.5 
months and 9.7 months (214 patients, p=0.001).
E L C w P  G U I D E L I N E S :
 A combination of cisplatin and etoposide is recommended 
in the management of limited disease small cell lung cancer 
with chest irradiation because this regimen is associated with 
better survival, its concomitant administration with chest 
irradiation is not-contraindicated in terms of toxicity and it 
has been used in the most recent significant trials performed 
in Ld SCLC.
Q U E S T I O N  6 :  S H O U L D  P R O P H y L A C T I C 
C R A N I A L  I R R A D I A T I O N  B E  P R O V I D E D ?  w H E N 
A N D  F O R  w H I C H  PA T I E N T S ?
Three societies recommend, in their guidelines, prophylactic 
cranial irradiation (PCI) in cases with complete response to 
treatment [11;56;57].
Two meta-analyses of the randomised trials performed 
in the eighties and early nineties on PCI have been published 
[58;59] As it is shown in table 6, both have demonstrated a 
survival benefit when PCI is restricted to patients with complete 
response to chemo(radio)therapy. There is also a benefit in 
terms of prevention of occurrence of brain metastases. Figure 
1 shows the results obtained by our meta-analysis of the trials 
of which the data allowed survival aggregation.
Five published trials were performed in complete respond-
ers [60-64]. The definition of CR was provided in only two. It 
was described in one study [60], as the disappearance of all 
signs and symptoms of disease, including normalization of all 
abnormal biomarkers lasting for a minimum of 30 days with 
TABLE 5. Randomised trials testing hyperfractionated radiotherapy for small cell lung cancer.
Reference Chemotherapy Arm Radiotherapy N pts OR SM p
Turrisi,
1999 [50]
CddP-VP16 (x4)
early concurrent
- standard 45 Gy/ 1.8 per d/ in 5 w 206 87% 19 m (16% 5 yr) 0.04
- bifractionated 45 Gy/ bid/ 30x in 3 w 211 87% 23 m (26% 5 yr)
Bonner,
1999 [51]
CddP-VP16 (x6)
late concurrent
- standard cycles 4-5 50.4 Gy 1.8/d in 28 x 132 20.6 m (21% 5 yr) NS
- bifractionated cycles 4-5 48 Gy in 32x with split 130 20.6 m (22% 5 yr)
N: number; CT: chemotherapy; OR: objective response; pts: patients; MST: median survival time; w: week; m: month; d: day; yr: year; NS: non 
significant; VP16: etoposide; CddP: cisplatin.
TABLE 6. Meta-analyses performed on the role of prophylactic cranial irradiation in SCLC.
Reference Methodology Outcome N trials N pts Survival results
Auperin, 1999 (58) Individual patients data Overall survival 6 (CR) 987 S in favour PCI
Meert, 2001 (59) Systematic review Overall survival 11 (global) 1518 NS
6 (CR) 865 S in favour PCI
N: number; pts: patients; CR: complete response; PCI: prophylactic cranial irradiation; S: significant; NS: non significant.
FIGURE 1. Results of the ELCWP meta-analysis [59] of the 
studies evaluating the role of PCI in SCLC on survival when 
patients are in CR: HR: 0.82 (95% CI: 0.71-0.96).
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a work-up where all previously positive suspicious tests had 
to be repeated and in the other [62], as the disappearance of 
all tumour confirmed by the chest film and microscopic and 
histological evaluation at the time of bronchoscopy with a 
work-up including brain CT scan and all previously positive 
suspicious tests.
E L C w P  G U I D E L I N E S :
Prophylactic cranial irradiation can be proposed in pa-
tients with limited disease small cell lung cancer, in cases 
with complete response to treatment if the response assess-
ment and the assessment work-up are similar to those used 
in the relevant trials and if a similar definition of complete 
response is used.
Q U E S T I O N  7 :  w H A T  I S  T H E  A D D I T I O N A L  R O L E 
O F  T H O R A C I C  S U R G E R y  I N  E A R Ly  S C L C  ?
For RCR [11], thoracic surgery is not routinely recom-
mended as primary therapy. In cases of biopsy excision of 
a peripheral nodule, chemotherapy has to be administered. 
For ACCP [65], surgery can be offered in case of very limited 
disease (stage T1-2 N0) and has to be followed by platinum-
based chemotherapy. Two old randomised trials are available 
(table 7), one testing radiotherapy versus surgery [66] and the 
other testing the additional role of surgery after induction 
chemotherapy [67]. Both were performed in patients with bulky 
SCLC and none showed a benefit of surgery. Many small series 
published encouraging results with surgery [68]. Two indica-
tions can be stated: solitary pulmonary nodules [69-71] and 
central very limited disease (N0 or N1) [70;72]. Surgery may 
also be proposed as salvage therapy in rare cases of residual 
disease due to non-small cell lung histology in the context of 
a mixed tumour [73].
E L C w P  G U I D E L I N E S :
 The additional role of surgery in limited disease SCLC is 
controversial. It has nevertheless some potential indications 
such as: the peripheral nodule, stage I (T1 N0, T2 N0) disease 
(called very limited disease) and residual disease after induc-
tion chemo(radio)therapy in the case of histological mixed 
tumour. Surgery should be performed using the guidelines 
recommended for non-small cell lung cancer. When surgery 
is initially performed, adjuvant chemotherapy should be ad-
ministered. For centrally localized SCLC, surgery should only 
be performed in the context of a clinical trial.
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